Natco Pharma Ltd. (NATP)

NSE
Currency in INR
869.05
-0.15(-0.02%)
Closed·
NATP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NATP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
867.45882.70
52 wk Range
726.801,639.00
Key Statistics
Edit
Bid/Ask
869.25 / 869.10
Prev. Close
869.2
Open
882.1
Day's Range
867.45-882.7
52 wk Range
726.8-1,639
Volume
347.37K
Average Volume (3m)
1.05M
1-Year Change
-27.61%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NATP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
967.45
Upside
+11.32%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Natco Pharma Ltd. News & Analysis

Show more

Natco Pharma Company Profile

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Employees
4016
Market
India

Compare NATP to Peers and Sector

Metrics to compare
NATP
Peers
Sector
Relationship
P/E Ratio
8.3x33.6x−0.5x
PEG Ratio
0.230.850.00
Price/Book
2.1x5.4x2.6x
Price / LTM Sales
3.5x6.1x3.0x
Upside (Analyst Target)
9.5%10.4%52.5%
Fair Value Upside
Unlock−5.9%8.7%Unlock

Analyst Ratings

3 Buy
3 Hold
4 Sell
Ratings:
10 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 967.45
(+11.32% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 105.26%
Dividend Yield
0.69%
Industry Median 0.69%
Annualised payout
6.00
Paid unevenly
5-Years Growth
-2.33%
Growth Streak

Earnings

Latest Release
May 28, 2025
EPS / Forecast
22.85 / 32.20
Revenue / Forecast
12.21B / 14.36B
EPS Revisions
Last 90 days

NATP Income Statement

FAQ

What Is the Natco Pharma (NATP) Stock Price Today?

The Natco Pharma stock price today is 869.05.

What Stock Exchange Does Natco Pharma Trade On?

Natco Pharma is listed and trades on the India National Stock Exchange stock exchange.

What Is the Stock Symbol for Natco Pharma?

The stock symbol for Natco Pharma is "NATP."

Does Natco Pharma Pay Dividends? What’s The Current Dividend Yield?

The Natco Pharma dividend yield is 0.69%.

What Is the Natco Pharma Market Cap?

As of today, Natco Pharma market cap is 155.47B.

What Is Natco Pharma's Earnings Per Share (TTM)?

The Natco Pharma EPS (TTM) is 105.26.

When Is the Next Natco Pharma Earnings Date?

Natco Pharma will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is NATP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Natco Pharma Stock Split?

Natco Pharma has split 1 times.

How Many Employees Does Natco Pharma Have?

Natco Pharma has 4016 employees.

What is the current trading status of Natco Pharma (NATP)?

As of 24 Jun 2025, Natco Pharma (NATP) is trading at a price of 869.05, with a previous close of 869.20. The stock has fluctuated within a day range of 867.45 to 882.70, while its 52-week range spans from 726.80 to 1,639.00.

What Is Natco Pharma (NATP) Price Target According to Analysts?

The average 12-month price target for Natco Pharma is INR967.45455, with a high estimate of INR1480 and a low estimate of INR697. 3 analysts recommend buying the stock, while 4 suggest selling, leading to an overall rating of Neutral. The stock has an +11.32% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.